Magnolia Medical appoints Sarah Huber as Senior VP Sales

Magnolia Medical Technologies, Inc., the inventor of the Steripath Initial Specimen Diversion Device platform and the ISDD market to prevent false-positive sepsis test results, announced the appointment of Sarah Huber as Senior Vice President of Sales. Sarah will lead Magnolia Medical's U.S. sales organisation, overseeing commercial strategy and execution to accelerate adoption of the Steripath platform across hospitals and healthcare systems nationwide.

Huber is a seasoned sales and commercial executive with more than two decades of leadership experience in healthcare and medical device sales. She brings deep expertise in building and scaling high-performance sales organisations, expanding market presence, and successfully launching innovative medical technologies across a wide range of clinical settings.

Most recently, Huber served as Vice President of Sales at Pulmonx Corporation, where she led the U.S. sales organisation and played a key role in driving revenue growth, cultivating customer relationships, and increasing adoption of advanced respiratory solutions for obstructive lung disease. Throughout her career, she has held senior sales leadership roles at leading medical technology organisations, including Boston Scientific, BTG, and Conceptus.

"We are thrilled to have Sarah join our senior management team and lead the commercial organisation," said Jason Richey, President and Chief Executive Officer of Magnolia Medical. "She has an impeccable record of leading dynamic and fast-growing sales organisations. She has proven her ability to generate significant value by scaling both the revenue and profitability of the organisations she's joined. Her extensive background in a solution-focused, customer-first sales approach makes her an ideal fit based on our continued commitment to delight our growing base of Steripath customers."

Huber's background spans disposable, implantable, and capital medical technologies, with a consistent track record of exceeding growth targets and leading cross-functional teams through periods of rapid commercialisation and market expansion.

"I am excited to join Magnolia Medical at such a pivotal time in the company's growth," said Huber. "Magnolia Medical's clinically proven technology is transforming the accuracy of blood culture diagnostics and improving patient care. I look forward to partnering with this talented team to deepen customer relationships, expand our commercial footprint, and help more hospitals benefit from the Steripath platform."